Artificial antigen presenting cells and methods of use
AssigneeRubius Therapeutics, Inc.
InventorsThomas Joseph Wickham, Tiffany Fen-yi Chen, Sivan Elloul, Regina Sophia Salvat, Nathan J. Dowden
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g. enucleated erythroid cells and platelets), that are engineered to activate or suppress T cells.
Claims40
An artificial antigen presenting cell (aAPC), wherein the aAPC comprises an enucleated cell, wherein the enucleated cell comprises on the cell surface at least one exogenous antigenic polypeptide disclosed in Table 1 or Tables 14-24.
2-8. (canceled)
11-12. (canceled)
An artificial antigen presenting cell (aAPC), wherein the aAPC comprises an enucleated cell, wherein the enucleated cell comprises on the cell surface an exogenous antigen-presenting polypeptide and an exogenous antigenic polypeptide, wherein the exogenous antigen-presenting polypeptide is an MHC class I single chain fusion protein or an MHC class II single chain fusion protein.
14-22. (canceled)
27-28. (canceled)
30-31. (canceled)
33-42. (canceled)
44-54. (canceled)
(canceled)
A method of treating a subject in need of an altered immune response, the method comprising:
- a) determining an expression profile of an antigen on a cell in the subject,
- b) selecting an artificial antigen presenting cell (aAPC), wherein the aAPC is an engineered enucleated cell comprising on the cell surface an antigen-presenting polypeptide and at least one first exogenous antigenic polypeptide, and
- c) administering the aAPC to the subject,
- thereby treating the subject in need of the altered immune response.
A method of treating a subject in need of an altered immune response, the method comprising:
- a) determining an HLA status of the subject,
- b) selecting an artificial antigen presenting cell (aAPC) that is immunologically compatible with the subject, wherein the aAPC is an engineered enucleated cell comprising on the cell surface at least one first exogenous antigenic polypeptide and at least one antigen-presenting polypeptide, and
- c) administering the aAPC to the subject,
- thereby treating the subject in need of the altered immune response.
(canceled)
68-69. (canceled)
(canceled)
73-74. (canceled)
(canceled)
78-84. (canceled)
Dependencies are inferred from the claim text.